Some investors asked questions on the investor interaction platform: Guangzhou savison medical technology, a pathological diagnosis company, recently added Guangzhou Wondfo Biotech Co.Ltd(300482) shareholders and increased its registered capital. Is it your company Guangzhou Wondfo Biotech Co.Ltd(300482) ? If yes, please introduce the company's vision of investing in pathological diagnosis industry. What will it do for future development? Does this belong to the same application scenario as the in-depth cooperation with Mindray? Does it mean that the company is increasing investment and expanding to pathological diagnosis?
Guangzhou Wondfo Biotech Co.Ltd(300482) (300482. SZ) said on the investor interaction platform on January 5 that savison technology is committed to providing the whole process solution of intelligent pathological AI assisted diagnosis. The company's investment in savison technology is to further expand the layout of the field of pathological diagnosis. The two sides complement each other in terms of technology and market. Through cooperation, the business chain of "swelling - immunohistochemistry - Digital Pathology - concomitant diagnosis" laid out by the company will be further improved, the ability to provide integrated solutions for the pathology department, improve the overall level of pathology detection business, and explore the second growth curve for the company's performance.
(Daily Economic News)
